Vertiv is teaming up with Generate Capital, PBC, on a "Bring Your Own Power & Cooling" (BYOP&C) solution for the US data center market. Vertiv has also announced a new digital twin offering and a ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. | Generate:Biomedicines is the latest biotech to benefit from a ...

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...

Generate:Biomedicines has hit the public markets as the world begins to question the usefulness of AI technology. CEO Mike Nally says biology is the key to unlocking the technology’s full potential.

Flagship Pioneering-founded Generate Biomedicines is tacking on a gigantic $273 million in series C funds, though the haul didn't reach the heights of the biotech’s previous $370 million raise back in ...

The Somerville-based company, which uses its proprietary AI system in drug engineering and development, is seeking to go public amid a jump in biotech and pharma IPO volume.

SAN FRANCISCO, Oct. 9, 2025 /PRNewswire/ -- Generate Capital, PBC ("Generate"), a leading infrastructure investment firm, today announced the closing of an $85 million tax equity commitment with ...

Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...

As part of its mission to open new sources of capital for the clean energy transition, Generate has deepened partnerships with insurance companies, pension plans and existing shareholders seeking ...